You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 10, 2024

NORVIR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Norvir patents expire, and when can generic versions of Norvir launch?

Norvir is a drug marketed by Abbott and Abbvie and is included in five NDAs.

The generic ingredient in NORVIR is ritonavir. There are twenty-one drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the ritonavir profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Norvir

A generic version of NORVIR was approved as ritonavir by CIPLA on January 15th, 2015.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NORVIR?
  • What are the global sales for NORVIR?
  • What is Average Wholesale Price for NORVIR?
Drug patent expirations by year for NORVIR
Drug Prices for NORVIR

See drug prices for NORVIR

Paragraph IV (Patent) Challenges for NORVIR
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
NORVIR Tablets ritonavir 100 mg 022417 1 2010-12-21

US Patents and Regulatory Information for NORVIR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbott NORVIR ritonavir CAPSULE;ORAL 020680-001 Mar 1, 1996 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie NORVIR ritonavir SOLUTION;ORAL 020659-001 Mar 1, 1996 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie NORVIR ritonavir CAPSULE;ORAL 020945-001 Jun 29, 1999 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie NORVIR ritonavir POWDER;ORAL 209512-001 Jun 7, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NORVIR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010 ⤷  Sign Up ⤷  Sign Up
Abbvie NORVIR ritonavir CAPSULE;ORAL 020945-001 Jun 29, 1999 ⤷  Sign Up ⤷  Sign Up
Abbvie NORVIR ritonavir SOLUTION;ORAL 020659-001 Mar 1, 1996 ⤷  Sign Up ⤷  Sign Up
Abbvie NORVIR ritonavir CAPSULE;ORAL 020945-001 Jun 29, 1999 ⤷  Sign Up ⤷  Sign Up
Abbvie NORVIR ritonavir CAPSULE;ORAL 020945-001 Jun 29, 1999 ⤷  Sign Up ⤷  Sign Up
Abbvie NORVIR ritonavir CAPSULE;ORAL 020945-001 Jun 29, 1999 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for NORVIR

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Mylan S.A.S Ritonavir Mylan ritonavir EMEA/H/C/004549
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV 1 infected patients (adults and children of 2 years of age and older).
Authorised yes no no 2017-11-09
AbbVie Deutschland GmbH Co. KG Norvir ritonavir EMEA/H/C/000127
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1-infected patients (adults and children of two years of age and older).
Authorised no no no 1996-08-25
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for NORVIR

See the table below for patents covering NORVIR around the world.

Country Patent Number Title Estimated Expiration
Greece 950300059 ⤷  Sign Up
Poland 2206500 ⤷  Sign Up
New Zealand 560829 A solid pharmaceutical dosage formulation ⤷  Sign Up
Peru 20100123 UNA FORMULACION SOLIDA DE DOSIFICACION FARMACEUTICA ⤷  Sign Up
South Korea 100187613 ⤷  Sign Up
Austria 196761 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NORVIR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0674513 C300060 Netherlands ⤷  Sign Up PRODUCT NAME: RITONAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF EEN FARMACEUTISCH AANVAARDBARE ESTER, EN LOPINAVIR; REGISTRATION NO/DATE: EU/1/01/172/001 - EU/1/01/172/003 20010320
0674513 SPC/GB01/044 United Kingdom ⤷  Sign Up PRODUCT NAME: THE COMBINATION OF THE ACTIVE INGREDIENTS RITONAVIR AND LOPINAVIR; REGISTERED: CH 55649 20001213; UK EU/1/01/172/001 20010320; UK EU/1/01/172/002 20010320; UK EU/1/01/172/003 20010320
0674513 C00674513 Switzerland ⤷  Sign Up PRODUCT NAME: LOPINAVIR UND RITONAVIR; REGISTRATION NO/DATE: IKS 55648 20001213
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.